Are you ready to boost your leadership skills in EASL’s governance? EASL is now looking to fill the following positions: Vice-Secretary Treasurer Public Health Councillor One Scientific Committee Member Two Young Investigators Task Force Members Two Nurses & AHPs Task Force Members
The EASL Congress 2023 is around the corner, and we are looking for our next awardees to celebrate.
In a joint effort, EASL, together with the International Liver Transplantation Society (ILTS) and the American Association for the Study of Liver Diseases (AASLD), is launching a survey aimed at transplant centres worldwide on the utilization of HbsAg-positive organs in…
About JHEP Reports Published since 2019, JHEP Reports is EASL’s first open access journal with a 2021 Impact Factor of 9.917. JHEP Reports is an innovative Journal publishing articles on global issues in hepatology, with specific focus on clinical trials,…
This October 2022, in honour of Liver Cancer Awareness Month, EASL participated in organising two important advocacy events aimed at identifying and implementing strategies to enhance awareness of liver cancer and engage key policymakers at the EU level.
Amsterdam, October 6, 2022 – A new analysis reveals that primary liver cancer was among the top three causes of cancer death in 46 countries in 2020 and the number of people diagnosed with or dying from primary liver cancer…
On 12-14 September 2022, representatives from civil society, partnering organizations, and the 53 Member States of the WHO European Region met in Tel Aviv, Israel for the 72nd governance session. The session was designed to assess progress and establish next…
Amsterdam, September 26, 2022 – Demand for donor livers for transplant patients outstrips supply with over 15% of waitlist patients dying after a year. A new international study offers support for increasing the use of living donor liver transplantation (LDLT)…
From the very beginning, EASL’s mission has been to be the “Home of Hepatology”. Providing education to everyone interested in hepatology and engaging with all stakeholders in the liver field wherever they are based. Through its 66 years of existence,…
Although DAA medications have demonstrated excellent safety and efficacy in non-pregnant individuals, they are not currently approved for HCV treatment in pregnant women due to a lack of safety data. Clinical trials assessing the safety of DAAs in pregnancy and…